146 related articles for article (PubMed ID: 34842282)
1. COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Kasperkiewicz M; Strong R; Mead K; Yale M; Zillikens D; Woodley DT; Recke A
Br J Dermatol; 2022 Apr; 186(4):737-739. PubMed ID: 34842282
[No Abstract] [Full Text] [Related]
2. Safety of the COVID-19 vaccine booster in patients with immunobullous diseases: A cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Kasperkiewicz M; Strong R; Yale M; Dunn P; Woodley DT
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e9-e10. PubMed ID: 35964297
[No Abstract] [Full Text] [Related]
3. Reply to 'The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?' by Damiani G et al.
Avallone G; Giordano S; Astrua C; Merli M; Senetta R; Conforti C; Ribero S; Marzano AV; Quaglino P
J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e433-e435. PubMed ID: 35067994
[No Abstract] [Full Text] [Related]
4. COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation.
Kasperkiewicz M; Yale M; Strong R; Zillikens D; Woodley DT; Recke A
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e418-e421. PubMed ID: 33724560
[No Abstract] [Full Text] [Related]
5. COVID-19 and autoimmune bullous diseases: Lessons learned.
Kasperkiewicz M; Woodley DT
Autoimmun Rev; 2023 Apr; 22(4):103286. PubMed ID: 36738951
[TBL] [Abstract][Full Text] [Related]
6. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?
Damiani G; Pacifico A; Pelloni F; Iorizzo M
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e645-e647. PubMed ID: 34169578
[No Abstract] [Full Text] [Related]
7. Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid.
Solimani F; Mesas-Fernández A; Bodner E; Carevic-Neri M; Hasheminasab M; Jakovljevicova T; Philipp A; Nast A; Worm M; Hilke FJ; Meier K; Ghoreschi K
J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e695-e697. PubMed ID: 36786360
[No Abstract] [Full Text] [Related]
8. Immunobullous diseases, prothrombotic state, and COVID-19: Role of prophylactic anticoagulation in bullous pemphigoid and pemphigus.
Anuragi RP; Kansal NK
Dermatol Ther; 2020 Nov; 33(6):e14361. PubMed ID: 33002264
[No Abstract] [Full Text] [Related]
9. Role of the International Pemphigus and Pemphigoid Foundation during the COVID-19 pandemic.
Kasperkiewicz M; Strong R; Yale M; Dunn P; Woodley DT
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e664-e665. PubMed ID: 35470479
[No Abstract] [Full Text] [Related]
10. Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset.
Russo R; Gasparini G; Cozzani E; D'Agostino F; Parodi A
Front Immunol; 2022; 13():834316. PubMed ID: 35251024
[No Abstract] [Full Text] [Related]
11. Risk of comorbid autoimmune diseases in patients with immunobullous disorders: A global large-scale cohort study.
Kasperkiewicz M; Vorobyev A; Bieber K; Kridin K; Ludwig RJ
J Am Acad Dermatol; 2023 Dec; 89(6):1269-1271. PubMed ID: 37562599
[No Abstract] [Full Text] [Related]
12. Comparison of the EUROIMMUN Dermatology Profile ELISA to the novel BIOCHIP Mosaic 7 for the diagnosis of immunobullous skin disease.
Simpson K; Scardamaglia L; Kok Y; Vu M; Kidd D; Yap T; Tran Y; Kern JS
Australas J Dermatol; 2021 Aug; 62(3):314-322. PubMed ID: 34080683
[TBL] [Abstract][Full Text] [Related]
13. The International Pemphigus and Pemphigoid Foundation.
Murrell DF; Werth VP; Segall J; Zrnchik W; Stuart M; Sirois D
Dermatol Clin; 2011 Oct; 29(4):655-7. PubMed ID: 21925013
[TBL] [Abstract][Full Text] [Related]
14. IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid.
Dainichi T; Chow Z; Kabashima K
J Dermatol Sci; 2017 Dec; 88(3):265-270. PubMed ID: 28747266
[TBL] [Abstract][Full Text] [Related]
15. Minocycline-induced hyperpigmentation in patients with pemphigus and pemphigoid.
Ozog DM; Gogstetter DS; Scott G; Gaspari AA
Arch Dermatol; 2000 Sep; 136(9):1133-8. PubMed ID: 10987869
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of pemphigus foliaceus and bullous pemphigoid. Demonstration of autoantibodies that bind to both the pemphigus foliaceus antigen complex and the bullous pemphigoid antigen.
Korman NJ; Stanley JR; Woodley DT
Arch Dermatol; 1991 Mar; 127(3):387-90. PubMed ID: 1998370
[TBL] [Abstract][Full Text] [Related]
17. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan.
Ogawa H; Sakuma M; Morioka S; Kitamura K; Sasai Y; Imamura S; Inaba Y
J Dermatol Sci; 1995 Mar; 9(2):136-41. PubMed ID: 7772576
[TBL] [Abstract][Full Text] [Related]
18. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid.
Alpsoy E; Akman-Karakas A; Uzun S
Arch Dermatol Res; 2015 May; 307(4):291-8. PubMed ID: 25589418
[TBL] [Abstract][Full Text] [Related]
19. Oral lesions in patients with pemphigus vulgaris and bullous pemphigoid.
Budimir J; Mihić LL; Situm M; Bulat V; Persić S; Tomljanović-Veselski M
Acta Clin Croat; 2008 Mar; 47(1):13-8. PubMed ID: 18714642
[TBL] [Abstract][Full Text] [Related]
20. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature.
Sami N; Ahmed AR
Dermatology; 2001; 202(4):293-301. PubMed ID: 11455140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
